Venetoclax + Ibrutinib as 1L Treatment in Patients With CLL: Meta-Analysis of RCTs

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Venetoclax + Ibrutinib as 1L Treatment in Patients With CLL: Meta-Analysis of RCTs

By XV Eurasian Hematology-Oncology Congress - EHOC 2024 FEATURING Ahmet Sarici

31 views

August 15, 2024

Comments 0

Leukemia

Pediatric ALL: Etiology, Diagnosis and Management

XV Eurasian Hematology-Oncology Congress - EHOC 2024

O. TüFekçI GüRocak

23 views

CML Case Discussion: Elderly Patients not Meeting ELN Milestones

XV Eurasian Hematology-Oncology Congress - EHOC 2024

M. Isam Sharif

9 views

CLL Case: Acquired Del(17p) at Relapse

XV Eurasian Hematology-Oncology Congress - EHOC 2024

M. Özer Çerme

8 views

ALL Case: B-ALL Arising During Len Maintenance in Myeloma Patient

XV Eurasian Hematology-Oncology Congress - EHOC 2024

K. Ozsoy

Novel Agents in the Treatment of R/R CLL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Jain

44 views

Venetoclax-Based Regimens in AML: Understanding Resistance and Devel…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Daver

120 views

Targeted Therapies in AML With a Focus on FLT3 Inhibitors

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Daver

38 views

A Clinical Case of Extranodal MZL of the Palatum Durum After CLL/SLL…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Ridova

9 views

Debates in CLL: Continuous or Finite Duration Therapy

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Jain

165 views

Ph+ ALL Management: Case-Based Discussion

XV Eurasian Hematology-Oncology Congress - EHOC 2024

K. Koruk

20 views

AML Case Discussion: FLT3-ITD+ High-Risk Disease

XV Eurasian Hematology-Oncology Congress - EHOC 2024

F. Hindilerden

25 views

Immunotherapy and Sequencing CD19-Targeted Therapies in Adults With …

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Jabbour

42 views

How I Treat R/R CML in 2024: Strategies and Emerging Therapies

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Jabbour

26 views

TKI Discontinuation in CML: Defining Eligibility Criteria and Predic…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

M. Yassin

29 views

A Case of CMML With Recurrent Skin Involvement

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Arslan Davulcu

13 views

Critical Re-Evaluation of Established Practices in CML Management

XV Eurasian Hematology-Oncology Congress - EHOC 2024

H. Kantarjian

173 views

Management of R/R AML: Treatment Options and Case Insights

XV Eurasian Hematology-Oncology Congress - EHOC 2024

V. Bonuomo

42 views

Debates in AML: 7+3 Is No Longer the Standard of Care

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Kadia

727 views

Practical Approach to MRD Monitoring in AML: Assessing Treatment Eff…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Kadia

108 views

Debates in Ph+ ALL: Allo-SCT Should Be Used Upfront in Adult Patients

XV Eurasian Hematology-Oncology Congress - EHOC 2024

D. Hoelzer

31 views

Debates in Ph+ ALL: Allo-SCT Is Not Necessary Upfront in Adult Patie…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Jabbour

43 views

CLL Case Discussion: First Line Treatment Strategies

XV Eurasian Hematology-Oncology Congress - EHOC 2024

D. Ortaboz

60 views

Incorporation of Targeted and Immunotherapies in ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

H. Kantarjian

230 views

CAR-T in R/R ALL: Case-Based Discussion of Lymphodepletion and Toxic…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Erdogan

15 views

The Importance of MRD in ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

F. Ravandi

183 views

Management of AML in Older Patients

XV Eurasian Hematology-Oncology Congress - EHOC 2024

F. Ravandi

204 views

Current Approaches to Managing T-Cell ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Ibrahim

23 views

TKI Toxicity Management in CML: A Case-Based Discussion

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Alshurafa

20 views

Management of Persistently MRD+ ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Odabasi Giden

36 views

Debates in AML: 3+7 is the SOC Induction Therapy for AML

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Uzay

58 views